SMT202100273T1 - Metodi e composizioni per il trattamento del cancro - Google Patents

Metodi e composizioni per il trattamento del cancro

Info

Publication number: SMT202100273T1
Authority: SM; San Marino
Prior art keywords: compositions; methods; treating cancer; cancer; treating
Prior art date: 2014-10-02

Application number

SM20210273T

Other languages

English (en)

Inventor

Alfredo Perales-Puchalt

Jose R Conejo-Garcia

Original Assignee

Wistar Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-02

Filing date

2015-09-30

Publication date

2021-07-12

2015-09-30 Application filed by Wistar Inst filed Critical Wistar Inst

2021-07-12 Publication of SMT202100273T1 publication Critical patent/SMT202100273T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hematology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)

SM20210273T 2014-10-02 2015-09-30 Metodi e composizioni per il trattamento del cancro SMT202100273T1 (it)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201462059068P	2014-10-02	2014-10-02
US201562202824P	2015-08-08	2015-08-08
EP15847792.7A EP3200815B1 (en)	2014-10-02	2015-09-30	Methods and compositions for treating cancer
PCT/US2015/053128 WO2016054153A1 (en)	2014-10-02	2015-09-30	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
SMT202100273T1 true SMT202100273T1 (it)	2021-07-12

Family

ID=55631412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20210273T SMT202100273T1 (it)	2014-10-02	2015-09-30	Metodi e composizioni per il trattamento del cancro

Country Status (16)

Country	Link
US (4)	US10259855B2 (it)
EP (1)	EP3200815B1 (it)
CN (2)	CN106999552B (it)
CA (1)	CA2989807C (it)
CY (1)	CY1125797T1 (it)
DK (1)	DK3200815T3 (it)
ES (1)	ES2870607T3 (it)
HR (1)	HRP20210705T1 (it)
HU (1)	HUE054673T2 (it)
LT (1)	LT3200815T (it)
PL (1)	PL3200815T3 (it)
PT (1)	PT3200815T (it)
RS (1)	RS61929B1 (it)
SI (1)	SI3200815T1 (it)
SM (1)	SMT202100273T1 (it)
WO (1)	WO2016054153A1 (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016073456A1 (en) *	2014-11-04	2016-05-12	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
EP3439698A1 (en) *	2016-04-05	2019-02-13	GlaxoSmithKline Intellectual Property Development Ltd	Inhibition of tgfbeta in immunotherapy
IT201600101852A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
RU2755000C2 (ru) *	2016-10-11	2021-09-08	Онкогреен Тхерапеутикс Са	Лиганды к рецептору фолликулостимулирующего гормона (FSH) в диагностике и лечении опухолей
IT201600101870A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
WO2019028096A1 (en)	2017-08-02	2019-02-07	The Wistar Institute Of Anatomy And Biology	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3676378A4 (en)	2017-08-31	2021-06-09	The New York Genome Center	PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS
EP3675878A4 (en)	2017-10-02	2021-06-16	Fred Hutchinson Cancer Research Center	LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
US20190211109A1 (en) *	2018-01-05	2019-07-11	Maxcyte, Inc.	Chronic car treatment for cancer
AU2019375036A1 (en) *	2018-11-05	2021-06-03	Centre Hospitalier Universitaire Vaudois	Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
WO2020146233A1 (en) *	2019-01-07	2020-07-16	H. Lee Moffitt Cancer Center And Research Institute Inc.	Foxp1-ablated chimeric cells
MX2021009186A (es) *	2019-01-30	2021-09-08	Wistar Inst	Captadores biespecificos de linfocitos t codificados por adn que se dirigen a antigenos de cancer y metodos de uso en tratamientos contra cancer.
JP2022526187A (ja) *	2019-04-12	2022-05-23	エモリーユニバーシティー	造血細胞の細胞傷害性を促進するための組成物及び方法
US20230107770A1 (en) *	2020-02-20	2023-04-06	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Method of enhancing immunotherapy using er stress pathway inhibitors
US20240101626A1 (en) *	2021-02-12	2024-03-28	Kar Muthumani	Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) *	2023-02-07	2023-12-01	徐州医科大学	利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5702702A (en)	1992-03-30	1997-12-30	The Wistar Institute Of Anatomy And Biology	Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
HU230364B1 (hu)	2001-11-21	2016-03-29	The Trustees Of The University Of Pennsylvania	Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US7081446B2 (en)	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
AU2003270063A1 (en)	2002-09-04	2004-03-29	The Trustees Of The University Of Pennsylvania	Immune cell receptor ligand and immune cell receptor
EP2000160A3 (en)	2002-10-30	2009-03-11	Gambro Lundia AB	Method and apparatuses for determining the efficiency of dialysis
DE602005017743D1 (de)	2004-01-23	2009-12-31	Angeletti P Ist Richerche Bio	Impfstoffträger für schimpansen-adenovirus
AU2006210443B2 (en)	2005-02-03	2011-01-27	Benitec, Inc.	RNAi expression constructs
GB0725201D0 (en) *	2007-12-24	2008-01-30	Asterion Ltd	Peptide fusion proteins
AU2009206212B2 (en)	2008-01-24	2014-01-16	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Lytic domain fusion constructs and methods of making and using same
EP2090322A1 (en)	2008-02-18	2009-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fsh receptor ligands for diagnosis and therapy of cancer
SG10201407908VA (en) *	2008-12-19	2015-01-29	Macrogenics Inc	Covalent diabodies and uses thereof
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US9708384B2 (en)	2011-09-22	2017-07-18	The Trustees Of The University Of Pennsylvania	Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
WO2013063019A1 (en)	2011-10-28	2013-05-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
JP2016506373A (ja) *	2012-11-15	2016-03-03	エスペランスファーマシューティカルズ，インコーポレイテッド	卵胞刺激ホルモン（ｆｓｈ）／溶解ドメイン融合コンストラクト及びその作製及び使用の方法
CN103509121B (zh) *	2012-11-22	2015-01-28	苏州康宁杰瑞生物科技有限公司	一种fsh融合蛋白及其制备方法和用途
WO2016073456A1 (en)	2014-11-04	2016-05-12	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor

2015
- 2015-09-30 WO PCT/US2015/053128 patent/WO2016054153A1/en not_active Ceased
- 2015-09-30 HR HRP20210705TT patent/HRP20210705T1/hr unknown
- 2015-09-30 HU HUE15847792A patent/HUE054673T2/hu unknown
- 2015-09-30 ES ES15847792T patent/ES2870607T3/es active Active
- 2015-09-30 CN CN201580065382.9A patent/CN106999552B/zh active Active
- 2015-09-30 SM SM20210273T patent/SMT202100273T1/it unknown
- 2015-09-30 EP EP15847792.7A patent/EP3200815B1/en active Active
- 2015-09-30 US US15/515,442 patent/US10259855B2/en active Active
- 2015-09-30 SI SI201531592T patent/SI3200815T1/sl unknown
- 2015-09-30 RS RS20210553A patent/RS61929B1/sr unknown
- 2015-09-30 PT PT158477927T patent/PT3200815T/pt unknown
- 2015-09-30 PL PL15847792T patent/PL3200815T3/pl unknown
- 2015-09-30 LT LTEP15847792.7T patent/LT3200815T/lt unknown
- 2015-09-30 CN CN202111464043.1A patent/CN114150018A/zh active Pending
- 2015-09-30 DK DK15847792.7T patent/DK3200815T3/da active
- 2015-09-30 CA CA2989807A patent/CA2989807C/en active Active
2019
- 2019-02-21 US US16/281,472 patent/US11248033B2/en active Active
2021
- 2021-05-31 CY CY20211100466T patent/CY1125797T1/el unknown
- 2021-12-27 US US17/562,643 patent/US12384826B2/en active Active
2025
- 2025-07-15 US US19/269,573 patent/US20250340609A1/en active Pending

Also Published As

Publication number	Publication date
DK3200815T3 (da)	2021-05-10
CN106999552B (zh)	2021-12-28
EP3200815A4 (en)	2018-04-25
HRP20210705T1 (hr)	2021-07-23
CN106999552A (zh)	2017-08-01
CN114150018A (zh)	2022-03-08
EP3200815B1 (en)	2021-03-03
US12384826B2 (en)	2025-08-12
US20190248862A1 (en)	2019-08-15
CA2989807C (en)	2023-07-04
CY1125797T1 (el)	2024-02-16
WO2016054153A1 (en)	2016-04-07
EP3200815A1 (en)	2017-08-09
PT3200815T (pt)	2021-05-07
US20170226176A1 (en)	2017-08-10
US20250340609A1 (en)	2025-11-06
SI3200815T1 (sl)	2021-11-30
HUE054673T2 (hu)	2021-09-28
US10259855B2 (en)	2019-04-16
US20220185861A1 (en)	2022-06-16
LT3200815T (lt)	2021-07-26
US11248033B2 (en)	2022-02-15
RS61929B1 (sr)	2021-06-30
PL3200815T3 (pl)	2021-10-18
ES2870607T3 (es)	2021-10-27
CA2989807A1 (en)	2016-04-07

Publication	Publication Date	Title
IL304820A (en)	2023-09-01	Preparations and methods for the treatment of cancer
AU2022231657A1 (en)	2022-10-13	Compositions and Methods for Treating Cancer
IL267247B (en)	2022-02-01	Compositions and methods for treating cancer
IL266053A (en)	2019-06-30	Preparations and methods for the treatment of ezh2-mediated cancer
IL252610A0 (en)	2017-07-31	Methods and preparations for the treatment of cancer
SG11201700079VA (en)	2017-02-27	Combination therapy compositions and methods for treating cancers
SG11201708861VA (en)	2017-11-29	Methods for treating cancer
PT3200815T (pt)	2021-05-07	Métodos e composições para o tratamento de cancro
IL256523A (en)	2018-02-28	Compositions and methods for treating cancer
IL251759A0 (en)	2017-06-29	Preparations and methods for treating insomnia
IL255638A (en)	2018-01-31	Compositions and methods for treating cancer
IL255022A0 (en)	2017-12-31	Cancer treatment methods
IL246558A0 (en)	2016-08-31	New methods of cancer treatment
EP3154544A4 (en)	2017-12-20	Compositions and methods for treating cancers
SG10202013112YA (en)	2021-02-25	Zinc-gamma-pga compositions and methods for treating cancer
IL255018A0 (en)	2017-12-31	Cancer treatment methods
ZA201703771B (en)	2020-11-25	Compositions and methods for treating hyperkalemia
ZA201605109B (en)	2017-09-27	Compositions and methods for treating neutropenia
IL255016A0 (en)	2017-12-31	Cancer treatment methods
ZA201802268B (en)	2019-01-30	Methods and compositions for preventing or treating cancer
IL252707B (en)	2020-01-30	Compositions and methods for treating diseases
EP3268028A4 (en)	2018-09-05	Compositions and methods for treating cancer
IL256763A (en)	2018-03-29	Compositions and methods for treating cancer
EP3160591A4 (en)	2018-04-04	Compositions and methods for treating cancer
HK40093247A (zh)	2024-01-05	治疗癌症的组合物及方法